Basiliximab: A review of its use as induction therapy in renal transplantation

BioDrugs

Volumn 24, Issue 1, 2010, Pages 55-76

  McKeage, Kate ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RABBIT DERIVED ANTITHYMOCYTE GLOBULIN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; CONSTIPATION; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INDUCED HYPOTENSION; INFECTION; INJECTION SITE REACTION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION TEST; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; METABOLIC DISORDER; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PAIN; PEDIATRICS; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ADULT; AGING; ANIMALS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; RECOMBINANT FUSION PROTEINS;

EID: 75149156618     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11203990-000000000-00000     Document Type: Review

References (117)

1. Ciancio G, Burke GW, Miller J. Induction therapy in renal transplantation: an overview of current developments. Drugs 2007; 67 (18): 2667-2680
2. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8 (3 Pt 2): 328-331
3. Arias M, Campistol JM, Vincenti F. Evolving treands in induction therapy. Transplant Rev 2009; 23: 94-102
4. Kälble T, Alcaraq A, Budde K, et al. European Association of Urology: guidelines on renal transplantation [online]. Available from URL: http:// www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/Renal-Transplant. pdf [Accessed 2009 Oct 12]
5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl. 3: S1-S157
6. Tang IY, Meier-Kriesche HU, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol 2007 Jul; 27 (4): 377-392
7. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003; 63 (24): 2803-2835
8. European Medicines Agency. Simulect® (basiliximab): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Simulect/H-207-PI-en.pdf [Accessed 2009 Sep 14]
9. Novartis Pharmaceuticals Corporation. Simulect® (basiliximab) for injection: prescribing information [online]. Available from URL: www.pharma.us. novartis.com/product/pi/pdf/simulect.pdf [Accessed 2009 Sep 7]
10. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995 Oct 15; 60: 748-756
11. European Medicines Agency. Simulect- (basiliximab): European public assessment report: scientific discussion [online]. Available from URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/Simulect/150298en6.pdf [Accessed 2009 Sep 14]
12. Binder M, Vogtle FN, Michelfelder S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007 Apr 15; 67 (8): 3518-3523
13. Baan CC, Van Riemsdijk-Overbeeke IC, Boelaars-Van Haperen MJAM, et al. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol 2002; 10 (1): 81-87
14. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999 Nov 15; 68 (9): 1288-1294
15. Haba T, Uchida K, Katayama A, et al. Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non- Japanese patients. Transplant Proc 2001 Nov 31; 33 (7-8): 3174-3175
16. Kovarik JM,Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proceedings 1996 Apr; 28 (2): 913-914
17. Sterkers G, Baudouin V, Ansart-Pirenne H, et al. Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients. Transplant Proc 2000 Dec; 32 (8): 2757-2759
18. Lebranchu Y, BridouxF,Buchler M, et al. Immunoprophylaxiswith basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002 Jan; 2 (1): 48-56
19. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin- 2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997 Dec 27; 64 (12): 1701-1705
20. Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposureresponse relationships in renal allotransplantation. Clin Transplant 1999 Feb; 13 (1 Pt 1): 32-38
21. Kovarik JM, Pescovitz MD, Sollinger HW, et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001 Apr; 15 (2): 123-130
22. Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients [letter]. Lancet 2000 Oct 14; 356 (9238): 1327-1328
23. Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002 Aug; 34: 1730-1732
24. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic- dynamic evaluations. Transplantation 2002 Oct 15; 74 (7): 966-971
25. Kovarik JM, Korn A, Chodoff L. Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplant Proc 2001 Nov-2001 31; 33 (7-8): 3172-3173
26. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999 Jan 27; 67 (2): 276-284
27. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetilcontaining triple therapy in renal transplantation. Transplantation 2003 Jan 15; 75 (1): 37-43
28. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 Oct 25; 350 (9086): 1193-1198
29. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001 Oct 15; 72 (7): 1261-1267
30. Parrott NR, Hammad AQ, Watson CJ, et al. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine A monotherapy in renal transplant recipients. Transplantation 2005 Feb 15; 79 (3): 344-348
31. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 Nov 9; 355 (19): 1967-1977
32. Kyllonen LE, Eklund BH, Pesonen EJ, et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007 Jul 15; 84 (1): 75-82
33. Mourad G, Rostaing L, LegendreC, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004 Aug 27; 78 (4): 584-590
34. Sollinger H, Kaplan B, PescovitzMD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001 Dec 27; 72 (12): 1915-1919
35. Tullius SG, Pratschke J, Strobelt V, et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 2003 Sep; 35 (6): 2100-2101
36. Hanaway M, Woodle ES, Mulgaonkar S, et al. 12 Month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no. 135]. Am J Transplant 2008 May; 8 Suppl. 2: 215
37. Mulgaonkar S, Hanaway M, Woodle ES, et al. Continuing 24 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no. 312]. Am J Transplant 2009 May 30; 9 Suppl. 2: 282
38. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003 Mar; 3 (3): 306-311
39. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008 Feb; 8 (2): 307-316
40. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens - tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: results of theAtlas study. Transplantation 2005 Dec 27; 80 (12): 1734-1741
41. KumarMS, Xiao SG, Fyfe B, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005 Feb; 19 (1): 61-69
42. Nematalla AH, Bakr MA, Gheith OA, et al. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007 Dec; 5 (2): 673-679
43. Andres A, Marcen R, Valdes F, et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant 2009 Jan; 23 (1): 23-32
44. Budde K, Bosmans JL, Sennesael J, et al. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric- coated mycophenolic acid and basiliximab. Clin Nephrol 2007 Mar; 67 (3): 164-175 (Pubitemid 46416377)
45. Cibrik D, Meier-Kriesche HU, Bresnahan B, et al. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant 2007 Mar; 21 (2): 192-201
46. Hernandez D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporinebased immunosuppression. Transplantation 2007 Sep 27; 84 (6): 706-714
47. Salvadori M, Scolari MP, Stefoni S, et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no. 108]. Transplantation 2008 Aug 11; 86 Suppl. 2: 39
48. Thistlethwaite JR Jr, Nashan B, Hall M, et al. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. Transplantation 2000 Sep 15; 70 (5): 784-790
49. Heldal K, Hartmann A, Leivestad T, et al. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity. Transplantation 2009 Apr 15; 87 (7): 1045-1051
50. Offner G, Toenshoff B, Hocker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008 Nov 15; 86 (9): 1241-1248
51. Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006 Jul; 6 (7): 1666-1672
52. Webb NJ, Prokurat S, Vondrak K, et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr Nephrol 2009 Jan; 24 (1): 177-182
53. Koch M, Becker T, Lueck R, et al. Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years? Biologics 2009; 3: 51-56
54. Sheashaa HA, Bakr MA, Ismail AM, et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 2003; 16: 393-398
55. Sheashaa HA, Bakr MA, Ismail AM, et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008 Oct; 12 (5): 376-381
56. Sheashaa HA, Bakr MA, Ismail AM, et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol 2005 May; 25 (3): 221-225
57. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003 Apr 12; 326 (7393): 789-793
58. Keown PA, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Biodrugs 2003; 17 (4): 271-279
59. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77 (2): 166-176
60. Shah MH, Bokhari MZ, Bokhari MT, et al. Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients. Transplant Proc 2003 Nov; 35 (7): 2737-2738
61. Lee BM, Oh CK, Jin SH, et al. Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Transplant Proc 2006 Sep; 38 (7): 2025-2028
62. Jorge S, Guerra J, Silva S, et al. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference? Transplant Proc 2008 Apr; 40 (3): 693-696
63. Goncalves LF, Ribeiro AR, Berdichevski R, et al. Basiliximab improves graft survival in renal transplant recipients with delayed graft function. Transplant Proc 2007 Mar; 39 (2): 437-438
64. Cho WH, Lee HJ, Kim HT, et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. Transplant Proc 2008 Sep; 40 (7): 2234-2236
65. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999 Apr; 67 (7): 1011-1018 (Pubitemid 29200852)
66. Al Najjar A, Etienne I, Le Pogamp P, et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006 Sep; 38 (7): 2298-2299
67. Pascher A, Ulrich F, Kohler S, et al. ATG versus basiliximab induction therapy in kidney allograft recipients receiving a dual immunosuppressive regimen: six-year results [abstract no. 800]. 22nd International Congress of the Transplantation Society 2008 Aug 14; 86 (2 Suppl.): 279
68. Brennan DC, Schnitzler M. 5 Year outcomes in a randomized trial comparing rabbit antithymocyte globulin and basiliximab in kidney transplant recipients: linking clinical trial data with registry data [abstract no. 798]. 22nd International Congress of the Transplantation Society 2008 Aug 14; 86 (2 Suppl.): 278
69. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005 Mar 27; 79 (6): 716-721
70. Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009 May 27; 87 (10): 1520-1529
71. Gavela Martinez E, Sancho Calabuig A, Escudero Quesada V, et al. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors. Transplant Proc 2008 Nov; 40 (9): 2900-2902
72. Yang SL, Wang D, Wu WZ, et al. Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol 2008 Jan; 18 (3): 281-285
73. Taber DJ,Weimert NA, Henderson F, et al. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc 2008 Dec; 40 (10): 3401-3407
74. Patolla V, Zhong X, ReedGW, et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832-1841
75. Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004 Sep 27; 78 (6): 904-910
76. Weng RR, Piper M, Foster CE. Rabbit anti-thymocyte globulin versus basiliximab in deceased donor renal transplants using a risk-adjusted protocol [abstract no. 1758]. Am J Transplant 2009; 9 (2 Suppl.): 676
77. Gabardi S, Martin S, Filkins B, et al. Induction therapy with rabbit antithymocyte globulin versus basiliximab and early steroid withdrawal in renal transplantation [abstract no. 1757]. Am J Transplant 2009; 9 (2 Suppl.): 675-676
78. Gurk-Turner C, BaigM,Munivenkatappa RB, et al. Superior renal allograft survival and decreased rejection with alemtuzumab induction compared to rabbit anti-thymocyte globulin or basiliximab [abstract no. 1754]. Am J Transplant 2009; 9 (2 Suppl.): 675
79. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction: long-term results. Am J Transplant 2005 Oct; 5 (10): 2539-2548
80. Chowdhury S, Kode RK, Ranganna K, et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. Transplant Proc 2001 Feb; 33 (1-2): 1057-1058
81. Kumar AM, Fa K, Vankawala R, et al. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone inAfrican American kidney recipients in reducing acute rejections and prolonging graft survival. Transplant Proc 2001 Nov; 33 (7-8): 3195-3196
82. Neamatalla AH, Bakr MA, Elagroudy AE, et al. Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant receipients: a prospective randomized controlled study single center experience (two year follow up) [abstract no. 163]. 13th Congress of the European Society for Organ Transplantation and the 15th European Transplant Coordinators Organization; 2007 Sep 29-Oct 3; Prague
83. Teraoka S, Sato S, SekijimaM, et al.Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid. Transplant Proc 2005 Mar; 37 (2): 791-794
84. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus. Am J Transplant 2005 Jan; 5 (1): 157-166
85. Kovac D, Kotnik V, Kandus A. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients. Transplant Proc 2005 Dec; 37 (10): 4230-4234
86. Tojimbara T, Sato S, Koyama I, et al. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil. Transplant Proc 2005 Mar; 37 (2): 895-898
87. Balbontin F, Kiberd B, Fraser A, et al. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period. Clin Transplant 2005 Apr; 19 (2): 225-229
88. Miura M, Harada H, Fukuzawa N, et al. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation. Clin Transplant 2005; 19 Suppl. 14: 54-58
89. Guba M, Rentsch M, Wimmer CD, et al. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transpl Int 2008 Jul; 21 (7): 637-645
90. Duzova A, Buyan N, Bakkaloglu M, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 2003 Dec; 35 (8): 2878-2880
91. Pape L, Strehlau J, Henne T, et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 2002 Feb; 17 (2): 276-280
92. Ojogho O, Sahney S, Cutler D, et al. Mycophenolatemofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Pediatr Transplant 2005 Feb; 9 (1): 80-83
93. Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001 Sep; 16 (9): 693-696
94. Clark G, Walsh G, Deshpande P, et al. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002 Jul; 17 (7): 1304-1309
95. Baron PW, Ojogho ON, Yorgin P, et al. Comparison of outcomes with lowdose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatr Transplant 2008 Feb; 12 (1): 32-39
96. Delucchi A, Valenzuela M, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs. Pediatr Transplant 2007 Nov; 11 (7): 743-748
97. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 2005 Aug; 9 (4): 456-463
98. Valenzuela M, Delucchi A, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report. Transplant Proc 2008 Nov; 40 (9): 3237-3240
99. Montini G, Murer L, Ghio L, et al. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int 2005 Jan; 18 (1): 36-42
100. McDonald RA, Smith JM, HoM, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008 May; 8 (5): 984-989
101. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 2007 Jan; 7 (1): 137-148
102. National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults [online]. Available from URL: http://www.nice.org. uk/nicemedia/pdf/TA085guidance.pdf [Accessed 2009 Oct 12]
103. National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in children and adolescents [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA099guidance.pdf [Accessed 2009 Oct 12]
104. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. Biodrugs 2005; 19 (1): 39-46
105. Webster AC, Playford EG, Higgins GY, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2009; (3): CD003897
106. Knoll G. Trends in kidney transplantation over the past decade. Drugs 2006; 68 Suppl. 1: 3-10
107. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009; 22: 38-48
108. Webster AC, Lee VWS, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006; (2): CD004290
109. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009 Apr; 87 (8 Suppl.): 1-6
110. Sarwal MM. Out with the old, in with the new: immunosuppression minimization in children. Curr Opin Organ Transplant 2008; 13: 513-521
111. Lorber MI, Fastenau J, WilsonD, et al. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant 2000 Oct; 14 (5): 479-485
112. Walters SJ, Whitfield M, Akehurst RL, et al. Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant Proc 2001 Nov 31; 33 (7-8): 3187-3191
113. Chilcott JB, Holmes MW, Walters S, et al. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transpl Int 2002 Oct; 15 (9-10): 486-493
114. Morton RL, Howard K, Webster AC, et al. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant 2009 Jul; 24 (7): 2258-2269
115. Emparan C, Wolters H, Laukotte M, et al. The cost-effectiveness of basiliximab induction in 'old-to-old' kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis. Transplant Proc 2005 Jun; 37 (5): 2069-2071
116. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 Aug; 353 (8): 770-781
117. Wissing KM, Fomegne G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008 Feb 15; 85 (3): 411-416